SciSparc (SPRC) Operating Expenses (2016 - 2022)

SciSparc (SPRC) posted Operating Expenses of $1.5 million for Q4 2022, down 20.44% sequentially from $1.9 million in Q3 2022.

SciSparc (SPRC) Operating Expenses (2016 - 2022) Analysis & Trends

SciSparc has reported Operating Expenses for 5 years, with the latest figure at $1.5 million in Q4 2022.

Quarterly Operating Expenses changed N/A year-over-year to $1.5 million in Q4 2022, while the trailing twelve-month figure through Jun 2024 was $1.5 million (down 55.69% YoY) and the FY2025 annual result came in at $8.5 million, up 11.76% from the prior year.
Operating Expenses fell to $1.5 million in Q4 2022 per SPRC's latest filing, from $1.9 million in the prior quarter.
Over five years, Operating Expenses peaked at $2.1 million in Q1 2018 and troughed at $802000.0 in Q1 2019.
A 3-year average of $1.6 million and a median of $1.6 million in 2018 frame the typical range for Operating Expenses.
The sharpest annual moves came in 2018 and 2019: Operating Expenses soared 230.85% in 2018, then tumbled 62.42% in 2019.
Over 3 years, Operating Expenses stood at $1.6 million in 2018, then retreated by 20.52% to $1.2 million in 2019, then grew by 21.41% to $1.5 million in 2022.
According to Business Quant data, Operating Expenses over the past three periods registered $1.5 million, $1.9 million, and $1.2 million for Q4 2022, Q3 2022, and Q2 2019 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Opex (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	2.09 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	3.00 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	2.89 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	960.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.21 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	1.06 Bn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	427.03 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	541.02 Mn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-784.57 Mn
10	SciSparc	836,385.99	836,385.99	-	-

Download Data